MK-677 (ibutamoren): the oral "growth hormone" compound, honestly assessed

TL;DR

• Not a peptide - an orally active small-molecule ghrelin mimetic that survives digestion, so it works as a pill.
• It reliably works on the axis - raises 24-hour GH and IGF-1 by roughly 40–90%, sustained around the clock rather than pulsed.
• Its development programme was halted - at least one trial ended early over concern it might contribute to heart failure.
• Insulin resistance is documented - decreased insulin sensitivity, rising fasting glucose and increased HbA1c in human studies.
• FDA escalated through 2025–2026 - recalls, warning letters and public safety alerts referencing congestive-heart-failure risk.
• Lean-mass gains partly reflect fluid retention - functional and strength benefits are less clear than the IGF-1 numbers suggest.

MK-677 is the one you can take as a pill - which is exactly why it's popular and why it needs the most caution. It reliably raises GH and IGF-1, but it isn't a peptide, and it carries the clearest safety signals in the whole GH-axis category. Here's the honest assessment.

Educational content, not medical advice. No doses or protocols appear. MK-677 is investigational, not FDA-approved, and has documented effects on blood sugar and safety signals discussed below.

Updated September 2026: trims editorialising from the note on the 2026 evidence review; this page's safety position is unchanged. The halted development programme, the congestive-heart-failure concern and the blood-sugar effects were already stated here before the review, and the review corroborates them rather than changing them.

---

MK-677 shows up in every "GH peptide" conversation, so it belongs in the growth-hormone guide - with two immediate corrections. First, it isn't a peptide. Second, its convenience (it's oral, once-daily) is inseparable from its risk profile, which is the most concerning in this category. It genuinely works at raising GH and IGF-1. Whether that's a good trade is the honest question.

What MK-677 is - and why it isn't a peptide

MK-677 (ibutamoren) is an orally active, small-molecule ghrelin mimetic - a growth-hormone secretagogue that activates the same ghrelin receptor as ipamorelin, but as a non-peptide compound that survives digestion, so it works as a pill rather than an injection. That's the source of its appeal (no needles, once daily) and a big part of why it gets miscategorized. Calling it a "peptide" is wrong, and the distinction isn't pedantic - it's a different class of molecule with a different risk profile.

Mechanism - sustained elevation, no injection

By activating the ghrelin/GH-secretagogue receptor, MK-677 raises 24-hour GH exposure and IGF-1 by roughly 40–90% at standard research doses, and - unlike short-pulse injectables - it sustains that elevation around the clock from a single daily dose. In a 1996 Merck-funded trial, a single oral dose raised 24-hour GH secretion by about 97% in healthy elderly subjects, an effect maintained over weeks of daily use. So the "it works" claim is genuinely supported: MK-677 does what it says to GH and IGF-1.

What the human data shows

MK-677 is actually better studied in humans than most compounds in this space, with trials up to two years. That data shows increases in lean mass, IGF-1, sleep quality and appetite - but with an important asterisk: increased lean mass has often reflected fluid retention rather than pure muscle, and functional/strength benefits are less clear than the IGF-1 numbers suggest. It's a real physiological effect with an oversold interpretation.

The honest downsides - this is the important part

This is where MK-677 separates from the injectable secretagogues, and it deserves plain statement:

• Insulin resistance and blood sugar. Human studies show decreased insulin sensitivity, rising fasting glucose, and increased HbA1c. For anyone with insulin resistance, prediabetes or diabetes risk, this is a serious consideration, not a footnote.
• Fluid retention and appetite. Transient water retention and pronounced appetite stimulation are common (the appetite effect is sometimes the point, sometimes unwanted).
• A halted development program. MK-677's clinical development was stopped, and at least one trial was ended early over concerns it might contribute to heart failure - a signal no honest overview should omit.
• Enforcement and safety alerts. Through 2025–2026 the FDA escalated action on MK-677 with recalls, warning letters, and public safety alerts referencing congestive-heart-failure risk.

What the 2026 evidence review added

On 8 September 2026, UCLA Health published a review in The American Journal of Sports Medicine covering 565 studies across six widely marketed compounds - BPC-157, TB-500, CJC-1295, ipamorelin, GHK-Cu and MK-677. Across the set, more than two-thirds of the underlying studies were animal-only and the human work was mostly small and short - a description of how much research exists, and of what kind.

MK-677 sits differently within that group on both counts. On evidence volume it comes off better than its companions: it has genuine multi-year human trials, which most of the six do not. On safety it comes off worse - the review named the halted MK-677 trial, stopped over congestive-heart-failure risk, as one of its two headline safety findings.

That is the honest summary of this compound, and it is why it is handled more cautiously here than anything else in the category. The safety signals on this page do not come from an absence of data. They come from the data that exists.

Regulatory and sourcing status

MK-677 is not FDA-approved for any use; its Phase II development was halted on safety grounds. It's widely sold "for research use only" - the disclaimer that shifts all liability to the buyer - and carries the same unverified-purity risks as the rest of the grey market, on top of its own physiological cautions. The general peptide side-effect cautions apply, plus the blood-sugar and cardiac signals specific to this compound.

MK-677 vs injectable GH secretagogues

The trade is convenience for control. MK-677 gives sustained, oral, hands-off GH/IGF-1 elevation - but that around-the-clock elevation is less physiologic than a pulse, and it comes bundled with the insulin and cardiac signals above. Injectable options like ipamorelin with a GHRH analog are less convenient but produce a more pulse-like, arguably more physiologic signal, and (for ipamorelin) a cleaner side-effect profile. Neither path is a free lunch; MK-677's is simply the one with the loudest safety signals.

The bottom line

MK-677 is the honest paradox of this category: the easiest to take, the best-studied, and the one with the most concerning safety data. It reliably raises GH and IGF-1 - but at a real cost to insulin sensitivity, with fluid retention, and against the backdrop of a development program halted over safety, including a cardiac signal. It is not a casual supplement. If GH-axis support is the goal, this is exactly the compound that most warrants a physician's screening - blood sugar and cardiovascular history especially - rather than a grey-market order.

If you're weighing MK-677, weigh it with a clinician. Vivre Labs focuses on monitored GH-axis support - typically injectable options like ipamorelin and CJC-1295, with baseline and follow-up bloodwork (including glucose and IGF-1) and honest risk-tiering. Book a consult to understand what a monitored alternative looks like. vivrelabs.com - Telegram · see the monitored V-G1 Build GH-axis protocol. (MK-677 availability varies; Vivre's emphasis is monitored GH-axis support.)

Frequently asked questions

Is MK-677 a peptide? No. It's an orally active small-molecule ghrelin mimetic (a GH secretagogue), not a peptide - a common misconception. It hits the same receptor as ipamorelin but is a different class of drug.

Is MK-677 safe? It's the GH-axis compound with the clearest safety concerns: reduced insulin sensitivity and higher blood sugar, fluid retention, and a development program halted partly over heart-failure concern. It's not FDA-approved. It warrants real medical screening, especially for blood sugar and cardiac history.

Does MK-677 raise blood sugar? Yes - human studies show decreased insulin sensitivity, higher fasting glucose and increased HbA1c. This is a key reason it needs supervision, particularly for anyone with diabetes risk.

MK-677 vs ipamorelin - which is better? Different tools. MK-677 is oral, sustained and convenient but carries more safety baggage; ipamorelin is injectable, pulse-like, selective and cleaner. Convenience vs a better side-effect profile - a supervised decision.

Related reading

• How growth-hormone peptides work - the GH/IGF-1 axis · Ipamorelin · Sermorelin vs CJC-1295 vs tesamorelin · Peptide side effects, honestly · GHRP-2, GHRP-6 and hexarelin · IGF-1: what the number tells you, and what it doesn't
• Growth hormone and cancer risk - MK-677 reliably raises IGF-1 and has no long-term oncological outcome data; this is the honest version of that question
• What 565 studies actually found about six popular peptides - the 2026 review that assessed MK-677 alongside five others
• PEG-MGF and the February 2027 docket - the other growth-axis compound covered here as a regulatory and evidence subject only
• Part of The Complete Guide to Growth-Hormone Peptides

---

Educational content, not medical advice. MK-677 is investigational, not FDA-approved; it reduces insulin sensitivity and raises blood glucose, and its development was halted partly over cardiac-safety concern. Physician-directed use with monitoring only. SEA-market claims are subject to MAB requirements.

References

• MK-677 (ibutamoren): oral non-peptide ghrelin-receptor agonist; ~40–90% rise in 24h GH/IGF-1; 1996 Merck trial (+~97% 24h GH, elderly). · Nass et al. - decreased insulin sensitivity, raised fasting glucose. · Halted Phase II development; trial stopped early over heart-failure concern. · FDA recalls/warning letters and CHF safety alerts (2025–2026). · WADA Prohibited List (S2). · UCLA Health / The American Journal of Sports Medicine review of 565 studies across BPC-157, TB-500, CJC-1295, ipamorelin, GHK-Cu and MK-677, published 8 September 2026: more than two-thirds of studies animal-only, human work generally low quality, and two named safety findings - a halted MK-677 trial (congestive-heart-failure risk) and a declared financial interest in one of the largest BPC-157 studies. (uclahealth.org; newsroom.ucla.edu.)